Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $751,200.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $25.04, for a total value of $751,200.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Joseph P. Lyssikatos also recently made the following trade(s):

• On Monday, April 1st, Joseph P. Lyssikatos sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.60, for a total value of $223,200.00.
• On Thursday, February 29th, Joseph P. Lyssikatos sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.42, for a total value of $197,040.00.
• On Monday, January 29th, Joseph P. Lyssikatos sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.85, for a total value of $190,200.00.

Enliven Therapeutics Stock Down 7.4 %

Shares of Enliven Therapeutics stock opened at $17.30 on Thursday. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $26.00. The stock has a market cap of $712.76 million, a PE ratio of -7.90 and a beta of 1.06. The business has a fifty day simple moving average of $16.98 and a 200 day simple moving average of $14.31.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. Analysts expect that Enliven Therapeutics, Inc. will post -2.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Mizuho started coverage on Enliven Therapeutics in a research note on Tuesday, April 9th. They set a “buy” rating and a $34.00 price objective for the company.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC acquired a new position in Enliven Therapeutics in the first quarter valued at about $36,000. Ameritas Investment Partners Inc. acquired a new position in Enliven Therapeutics in the second quarter valued at about $39,000. AJOVista LLC acquired a new position in Enliven Therapeutics in the fourth quarter valued at about $28,000. Royal Bank of Canada grew its stake in Enliven Therapeutics by 532.7% in the second quarter. Royal Bank of Canada now owns 3,075 shares of the company’s stock valued at $63,000 after acquiring an additional 2,589 shares during the period. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Enliven Therapeutics in the fourth quarter valued at about $66,000. 95.08% of the stock is owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.